Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

[VUBot]

On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) released interim Phase 1 results from its first-in-human trial of APG990. APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of approximately 60 days across doses tested. Key data from the 40-healthy subject trial showed: APG990…

Continue reading...